| Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy P Jayaprakash, M Ai, A Liu, P Budhani, T Bartkowiak, J Sheng, C Ager, ... The Journal of clinical investigation 128 (11), 5137-5149, 2018 | 329 | 2018 |
| Hsp90α and Hsp90β together operate a hypoxia and nutrient paucity stress‐response mechanism during wound healing P Jayaprakash, H Dong, M Zou, A Bhatia, K O'Brien, M Chen, DT Woodley, ... Journal of cell science 128 (8), 1475-1480, 2015 | 85 | 2015 |
| Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression M Zou, A Bhatia, H Dong, P Jayaprakash, J Guo, D Sahu, Y Hou, F Tsen, ... Oncogene 36 (15), 2160-2171, 2017 | 81 | 2017 |
| ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer RCE Hsieh, S Krishnan, RC Wu, AR Boda, A Liu, M Winkler, WH Hsu, ... Science immunology 7 (72), eabl9330, 2022 | 79 | 2022 |
| Breast cancer MDA-MB-231 cells use secreted heat shock protein-90alpha (Hsp90α) to survive a hostile hypoxic environment H Dong, M Zou, A Bhatia, P Jayaprakash, F Hofman, Q Ying, M Chen, ... Scientific reports 6 (1), 20605, 2016 | 78 | 2016 |
| A phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies A Hegde, P Jayaprakash, CA Couillault, S Piha-Paul, D Karp, J Rodon, ... Clinical Cancer Research 27 (11), 3050-3060, 2021 | 50 | 2021 |
| High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege CR Ager, A Boda, K Rajapakshe, ST Lea, ME Di Francesco, ... Journal for immunotherapy of cancer 9 (8), 2021 | 49 | 2021 |
| Melanoma evolves complete immunotherapy resistance through the acquisition of a hypermetabolic phenotype AR Jaiswal, AJ Liu, S Pudakalakatti, P Dutta, P Jayaprakash, ... Cancer immunology research 8 (11), 1365-1380, 2020 | 45 | 2020 |
| Hypoxia reduction sensitizes refractory cancers to immunotherapy P Jayaprakash, PDA Vignali, GM Delgoffe, MA Curran Annual Review of Medicine 73 (1), 251-265, 2022 | 44 | 2022 |
| PRAS40 connects microenvironmental stress signaling to exosome-mediated secretion J Guo, P Jayaprakash, J Dan, P Wise, GB Jang, C Liang, M Chen, ... Molecular and cellular biology, 2017 | 42 | 2017 |
| The anti-motility signaling mechanism of TGFβ3 that controls cell traffic during skin wound healing A Han, B Bandyopadhyay, P Jayaprakash, I Lua, D Sahu, M Chen, ... Biology open 1 (12), 1169-1177, 2012 | 20 | 2012 |
| Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors. M Reilley, AM Tsimberidou, SA Piha-Paul, TA Yap, S Fu, A Naing, ... Journal of Clinical Oncology 37 (15_suppl), TPS2669-TPS2669, 2019 | 14 | 2019 |
